These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 2046687)

  • 1. Neuroendocrine cell hyperplasia and neuroendocrine carcinoma of the rodent fundic stomach.
    Poynter D; Selway SA
    Mutat Res; 1991 Jun; 248(2):303-19. PubMed ID: 2046687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Omeprazole: its influence on gastric acid secretion, gastrin and ECL cells.
    Larsson H; Håkanson R; Mattsson H; Ryberg B; Sundler F; Carlsson E
    Toxicol Pathol; 1988; 16(2):267-72. PubMed ID: 3187355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gastric enterochromaffin-like cell hyperplasia and neoplasia in the rat: an indirect effect of the histamine H2-receptor antagonist, BL-6341.
    Hirth RS; Evans LD; Buroker RA; Oleson FB
    Toxicol Pathol; 1988; 16(2):273-87. PubMed ID: 2903543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gastric ECL-cell hyperplasia and carcinoids in rodents following chronic administration of H2-antagonists SK&F 93479 and oxmetidine and omeprazole.
    Betton GR; Dormer CS; Wells T; Pert P; Price CA; Buckley P
    Toxicol Pathol; 1988; 16(2):288-98. PubMed ID: 2903544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histamine as an intermediate growth factor in genesis of gastric ECLomas associated with hypergastrinemia in mastomys.
    Modlin IM; Kumar RR; Soroka CJ; Ahlman H; Nilsson O; Goldenring JR
    Dig Dis Sci; 1994 Jul; 39(7):1446-53. PubMed ID: 8026255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Omeprazole and ranitidine, antisecretagogues with different modes of action, are equally effective in causing hyperplasia of enterochromaffin-like cells in rat stomach.
    Ryberg B; Bishop AE; Bloom SR; Carlsson E; Håkanson R; Larsson H; Mattsson H; Polak JM; Sundler F
    Regul Pept; 1989 May; 25(2):235-46. PubMed ID: 2756157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is hypergastrinaemia dangerous to man?
    Creutzfeldt W; Lamberts R
    Scand J Gastroenterol Suppl; 1991; 180():179-91. PubMed ID: 1675024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacology of gastric acid inhibition.
    Shamburek RD; Schubert ML
    Baillieres Clin Gastroenterol; 1993 Mar; 7(1):23-54. PubMed ID: 8097411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological basis for the induction of gastric carcinoid tumours in the rat by loxtidine, an insurmountable histamine H2-receptor blocking drug.
    Brittain RT; Jack D; Reeves JJ; Stables R
    Br J Pharmacol; 1985 Aug; 85(4):843-7. PubMed ID: 4041682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of long lasting unsurmountable histamine H2 blockade and gastric carcinoid tumours in the rat.
    Poynter D; Pick CR; Harcourt RA; Selway SA; Ainge G; Harman IW; Spurling NW; Fluck PA; Cook JL
    Gut; 1985 Dec; 26(12):1284-95. PubMed ID: 2867954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gastrin and gastric enterochromaffin-like cell carcinoids in the rat.
    Carlsson E; Havu N; Mattsson H; Ekman L
    Digestion; 1990; 47 Suppl 1():17-23; discussion 49-52. PubMed ID: 2093010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathophysiology of the fundic enterochromaffin-like (ECL) cell and gastric carcinoid tumours.
    Modlin IM; Lawton GP; Miu K; Kidd M; Luque EA; Sandor A; Tang LH
    Ann R Coll Surg Engl; 1996 Mar; 78(2):133-8. PubMed ID: 8678447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Marked increase in gastric acid secretory capacity after omeprazole treatment.
    Waldum HL; Arnestad JS; Brenna E; Eide I; Syversen U; Sandvik AK
    Gut; 1996 Nov; 39(5):649-53. PubMed ID: 9026477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic inhibitory effects of gastrin and histamine receptor antagonists on Helicobacter-induced gastric cancer.
    Takaishi S; Cui G; Frederick DM; Carlson JE; Houghton J; Varro A; Dockray GJ; Ge Z; Whary MT; Rogers AB; Fox JG; Wang TC
    Gastroenterology; 2005 Jun; 128(7):1965-83. PubMed ID: 15940630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation and hyperplasia of gastrin and enterochromaffin-like cells in the stomach.
    Håkanson R; Böttcher G; Sundler F; Vallgren S
    Digestion; 1986; 35 Suppl 1():23-41. PubMed ID: 3539678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects on the rat oxyntic mucosa of the histamine2-antagonist loxtidine and the H+, K(+)-ATPase inhibitor omeprazole.
    Brenna E; Waldum HL; Sandvik AK; Schulze Søgnen B; Kristensen A
    Aliment Pharmacol Ther; 1992 Jun; 6(3):335-49. PubMed ID: 1600050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathophysiological effects of long-term acid suppression in man.
    McCloy RF; Arnold R; Bardhan KD; Cattan D; Klinkenberg-Knol E; Maton PN; Riddell RH; Sipponen P; Walan A
    Dig Dis Sci; 1995 Feb; 40(2 Suppl):96S-120S. PubMed ID: 7859587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gastric ECL-cell hyperplasia produces enhanced basal and stimulated gastric acid output but not gastric erosion formation in the rat.
    LePard KJ; Mohammed JR; Stephens RL
    Gen Pharmacol; 1997 Mar; 28(3):415-20. PubMed ID: 9068983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The CCK(2) receptor antagonist, YF476, inhibits Mastomys ECL cell hyperplasia and gastric carcinoid tumor development.
    Kidd M; Siddique ZL; Drozdov I; Gustafsson BI; Camp RL; Black JW; Boyce M; Modlin IM
    Regul Pept; 2010 Jun; 162(1-3):52-60. PubMed ID: 20144901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. H2-receptor blockade induces peptide YY and enteroglucagon-secreting gastric carcinoids in mastomys.
    Bilchik AJ; Nilsson O; Modlin IM; Sussman J; Zucker KA; Adrian TE
    Surgery; 1989 Dec; 106(6):1119-26; discussion 1026-7. PubMed ID: 2573958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.